spacer
home > ict > winter 2020 > think of the children: clinical trial considerations at home
PUBLICATIONS
International Clinical Trials

Think of the Children: Clinical Trial Considerations at Home




I recall writing my nursing degree dissertation 30 years ago on the ‘Passive Role of the Patient’. I was concentrating on diabetic patients in hospital undergoing treatment for reasons other than their diabetes. Management of their diabetes was taken away from them the moment they put on a gown and slippers; upon discharge from hospital, control returned and they resumed as masters of their condition! Now working in clinical trials, I am pleased to see that the terms ‘patient centricity’ and ‘patient empowerment’ are becoming common in our day-to-day language.

The time when all clinical trial visits were conducted at site has passed. We now see a hybrid between the site and home. The associated popularity of mobile research nursing services is widely seen as a positive move. We can now design clinical trials to better suit the needs and desires of the patients and give sites the support they deserve.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Illingworth Research Group is a provider of patient-centric clinical research solutions. This can be, but is not exclusive to, mobile research nursing, patient concierge, and medical photography. Services are operational in 45 countries and concentrate on taking the trial to the patient or making trial participation easier and more accessible to patients and their families.

illingworthresearch.com
Print this page
Send to a friend
Privacy statement
News and Press Releases

BRIM Biotechnology strengthens leadership team in preparation for transformational year ahead

Taipei, Taiwan, February 20th, 2023 / Sciad Newswire / BRIM Biotechnology, Inc. (BRIM, TPEx 6885), a clinical-stage company developing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases, is pleased to announce that Andrew Lin was elected as the new Chairman of the Board on 8th February, 2023, and that the new board has appointed Dr. Wen-Chyi Shyu as the company’s new Chief Executive Officer (CEO) from 1st March, 2023. The new leadership team will guide BRIM through what is set to be a transformational year for the company.
More info >>

White Papers

Quality By Design

Biopharma Group

Quality by Design (QbD) is a systematic approach to development that begins with the defined objectives and emphasizes science and quality risk management in order to achieve those goals. QbD ensures that the quality of the product is built into production processes from the outset, rather than being tested after development has already commenced.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement